Characteristic,Sales to assets ratio
Novo Nordisk,1.0
Roche,0.8
Merck & Co.,0.6
GlaxoSmithKline,0.5
Johnson & Johnson,0.5
Biogen,0.5
Lilly,0.5
Novartis,0.4
Gilead,0.4
AbbVie,0.4
Amgen,0.4
AstraZeneca,0.4
Mylan,0.4
Teva,0.3
Bristol-Myers Squibb,0.3
Pfizer,0.3
Sanofi,0.3
Endo,0.3
